AI FOR SCIENCE · ON THE RECORD
Aureka Biotechnologies
Designs antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
Full funding record →On the timeline →People filter →
Research on the record
- 2026-09-09Aureka opens up its agentic antibody-design harness, and 38 of 80 designs from it bound their target in the company's own labLevel 4 · Tested in the physical world
- 2026-07-04Aureka releases OpenDDE, an open co-folding model that predicts an acceptable interface for 66.4% of antibody-antigen complexes on a new test set it curated, against 51.0% for the next best modelLevel 2 · Computed
Graded by how far the evidence went, not how good the result is. See the methodology.
Also on the timeline
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Funding rounds tracked
- 2026-08-11Series B · $100MconfirmedLed by an unnamed industry investor (later tranche) · With Granite Asia, HighLight Capital · Existing investors Qiming Venture Partners, Matrix Partners China, NRL CapitalStated use: research and large-scale training of its next biological foundation model, and an upgraded Lab-in-the-Loop platform linking the model to its single-cell functional screening and high-throughput validation
Each round links to its line on the funding record, with its source.
Also in Protein design on the funding board
The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.
- 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
- 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
- 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
- 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
- 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.
- 2026-02-26Generate:BiomedicinesIPO · $400MA Flagship company using generative AI to design protein drugs such as antibodies, peptides and enzymes, and developing them itself.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.